Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Related Citations for PubMed (Select 17488390)

1.

Serum globulin levels in predicting the extent of hepatic fibrosis in patients with recurrent post-transplant hepatitis C infection.

Schmilovitz-Weiss H, Cohen M, Pappo O, Sulkes J, Braun M, Tur-Kaspa R, Ben-Ari Z.

Clin Transplant. 2007 May-Jun;21(3):391-7.

PMID:
17488390
2.

Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection.

Schmilovitz-Weiss H, Tovar A, Halpern M, Sulkes J, Braun M, Rotman Y, Tur-Kaspa R, Ben-Ari Z.

J Viral Hepat. 2006 Oct;13(10):671-7.

PMID:
16970598
3.

Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.

Katz LH, Mor E, Brown M, Bar-Nathan N, Shaharabani E, Sulkes J, Pappo O, Tur-Kaspa R, Ben-Ari Z.

Clin Transplant. 2006 Jul-Aug;20(4):465-70.

PMID:
16842523
4.

Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?

Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayón M, San Juan F, Landaverde C, Mir J, Berenguer J.

Liver Transpl. 2003 Nov;9(11):1152-8.

5.

Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection.

Watt K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N, Minuk GY.

J Viral Hepat. 2004 May;11(3):251-6.

PMID:
15117327
6.

Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.

Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G.

Liver Transpl. 2007 May;13(5):733-40.

7.

Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.

Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, Mela M, Manousou P, Senzolo M, Dhillon AP, Patch D, Burroughs AK.

Liver Transpl. 2007 Sep;13(9):1305-11.

8.

Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation.

Ben-Ari Z, Tambur AR, Pappo O, Sulkes J, Pravica V, Hutchinson I, Klein T, Tur-Kaspa R, Mor E.

Transplantation. 2006 Feb 15;81(3):392-7.

PMID:
16477226
9.

Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.

Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR.

Am J Transplant. 2008 Nov;8(11):2426-33. doi: 10.1111/j.1600-6143.2008.02362.x. Epub 2008 Aug 22.

10.

Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.

Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, Gentili F, Onetti Muda A, Berloco P, Rossi M, Attili AF, Gaudio E.

Dig Liver Dis. 2005 May;37(5):349-56.

PMID:
15843085
11.
12.

Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.

Toniutto P, Fabris C, Bitetto D, Falleti E, Avellini C, Rossi E, Smirne C, Minisini R, Pirisi M.

J Gastroenterol Hepatol. 2007 Nov;22(11):1904-8.

PMID:
17914968
13.

The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation.

Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN.

Liver Transpl. 2008 Sep;14(9):1287-93. doi: 10.1002/lt.21524.

14.

Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression.

Alkhouri N, Hanouneh IA, Lopez R, Zein NN.

Liver Transpl. 2010 Feb;16(2):155-62. doi: 10.1002/lt.21939.

15.

HCV-related fibrosis progression following liver transplantation: increase in recent years.

Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL.

J Hepatol. 2000 Apr;32(4):673-84.

PMID:
10782918
16.

Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence.

Micheloud D, Salcedo M, Bañares R, Rincón D, Lorente R, Muñoz-Fernández MA, Resino S.

Transpl Infect Dis. 2009 Apr;11(2):183-8. doi: 10.1111/j.1399-3062.2009.00370.x. Epub 2009 Feb 18.

PMID:
19254326
17.

Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.

Toniutto P, Fabris C, Avellini C, Minisini R, Bitetto D, Rossi E, Smirne C, Pirisi M.

World J Gastroenterol. 2005 Oct 14;11(38):5944-50.

18.

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.

Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P.

Liver Transpl. 2009 Jan;15(1):37-48. doi: 10.1002/lt.21566.

19.

[Treatment of recurrent HCV infection after liver transplantation].

Ostojić R.

Acta Med Croatica. 2005;59(5):443-6. Croatian.

PMID:
16381241
20.

Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.

Kuo A, Tan V, Lan B, Khalili M, Feng S, Roberts JP, Terrault NA.

Liver Transpl. 2008 Oct;14(10):1491-7. doi: 10.1002/lt.21548.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk